Liver International

Papers
(The H4-Index of Liver International is 38. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Issue Information236
Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct‐acting antivirals122
A population‐based study of pyogenic liver abscess in Korea: Incidence, mortality and temporal trends during 2007‐2017101
Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT‐FOXO3 signalling pathway100
Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis96
Golexanolone improves fatigue, motor incoordination and gait and memory in rats with bile duct ligation85
RETRACTION: Interferons α, β, γ Each Inhibit Hepatitis C Virus Replication at the Level of Internal Ribosome Entry Site‐Mediated Translation84
Perilipin 5 protects the mitochondrial oxidative functions and improves the alcoholic liver injury in mice79
HBV cure—The light at the end of the tunnel?73
Fatty liver disease at the basis of cardiac remodelling and increased heart rate: Insights from the UK Biobank67
Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort66
Time since liver transplant and immunosuppression withdrawal outcomes: Systematic review and individual patient data meta‐analysis65
Importance of gender differences in body composition for liver transplantation and the ‘Sarco‐Model’ study64
Navigating portal hypertension: Unlocking safe passage to healthy pregnancy in EHPVO61
Inside Front Cover59
Is ageing a problematic hurdle to the efficacy of first‐line atezolizumab plus bevacizumab in hepatocellular carcinoma?58
Letter to the Editor regarding “Long‐term exposure to air pollution and incident non‐alcoholic fatty liver disease and cirrhosis”57
Different methodologies of protein induced by vitamin K absence or antagonist II in patients without hepatocellular carcinoma56
Changing epidemiological features of hepatocellular carcinoma: Taiwan's position56
High disease burden and healthcare resource usage in patients with acute porphyria—A population‐based analysis56
Issue Cover55
Interpreting elevated liver blood test results through a genetic lens: A genome‐wide association study52
Think twice about IgG4‐related diseases before operating on hepatic masses52
Is fresh frozen plasma transfusion associated with outcomes in acute variceal bleeding?50
High prevalence of porto‐sinusoidal vascular disease in patients with constantly elevated gamma‐glutamyl transferase levels49
Bringing evidence to the MAFLD‐MASLD debate48
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease46
Autoimmune hepatitis triggered by COVID‐19: A report of two cases46
Impact of socio‐economic environment on incidence of primary liver cancer in France between 2006 and 201644
Immunogenicity and safety of a third dose of anti‐SARS‐CoV‐2 BNT16b2 vaccine in liver transplant recipients44
The integrated stress response‐related expression of CHOP due to mitochondrial toxicity is a warning sign for DILI liability42
Cardiac Geometry in Cirrhosis: Translation to Public Health and Trial Design41
Alcohol‐related hepatocellular carcinoma is a heterogenous condition: Lessons from a latent class analysis41
Prognosis of hospitalized patients with cirrhosis and acute kidney disease39
Hospitalisations With Cryoglobulin‐Related Diseases in Spain Over 25 Years38
Helicobacter pylori‐Associated Surrogate Markers of Intestinal Permeability, Bacterial Translocation and Gut Barrier Damage in Liver Cirrhosis38
Correction to ‘Development and Validation of an Image Biomarker to Identify Metabolic Dysfunction Associated Steatohepatitis: MR‐MASH Score’38
A Markov Model Unveiling the Impact of Resmetirom on the Natural History of MASLD Patients: A Sistematic Review and Meta‐Analysis38
Causal effect of lower birthweight on non‐alcoholic fatty liver disease and mediating roles of insulin resistance and metabolites38
0.064246892929077